Allergan Nears to Sign a Takeover Deal with Actavis

Actavis is on the edge to acquire Allergan Inc. with a worth of $65.5 billion. It would surely be the biggest deal of 2014.

Valeant Pharmaceuticals, and Actavis investor William Ackman’s Pershing Square Capital Management tried really hard to convince the owners of Allergan for this merger.  An the end of October, The authority also increased its offer up to $200 on every share.

On the other hand, the company raised its proposal specially at the request of Allergan.  In October, Valeant sent a letter directly to the directors of Allergan in which it stated that the company will re-consider this deal if  Allergan increases its offer.

The board of directors of Actavis arranged a meeting with Allergan in order to reexamine the cash and stock takeover. However, the company intends to officially announce the deal on Monday. As per the conditions of the deal, Actavis will pay Allergan an amount of $215 and $220 per share.

This kind of deal will surely put the Allergan in an unreachable place for Valeant.  Nevertheless, if both the companies agreed on this deal, then it will certainly be the biggest merger of this year.

On the other hand, the spokesman of the two companies refused to make a comment on this particular matter.  However, Pershing Square was not available for comment.